KR20250004357A - 골수증식 장애의 치료 방법 - Google Patents

골수증식 장애의 치료 방법 Download PDF

Info

Publication number
KR20250004357A
KR20250004357A KR1020247040010A KR20247040010A KR20250004357A KR 20250004357 A KR20250004357 A KR 20250004357A KR 1020247040010 A KR1020247040010 A KR 1020247040010A KR 20247040010 A KR20247040010 A KR 20247040010A KR 20250004357 A KR20250004357 A KR 20250004357A
Authority
KR
South Korea
Prior art keywords
ruxolitinib
subject
compound
treatment
myelofibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247040010A
Other languages
English (en)
Korean (ko)
Inventor
아드리안 센더로비츠
마이클 쿠퍼
Original Assignee
콘스텔레이션 파마슈티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 콘스텔레이션 파마슈티칼스, 인크. filed Critical 콘스텔레이션 파마슈티칼스, 인크.
Publication of KR20250004357A publication Critical patent/KR20250004357A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020247040010A 2018-11-27 2018-11-27 골수증식 장애의 치료 방법 Pending KR20250004357A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020217019508A KR102738936B1 (ko) 2018-11-27 2018-11-27 골수증식 장애의 치료 방법
PCT/US2018/062534 WO2020112086A1 (en) 2018-11-27 2018-11-27 Methods of treating myeloproliferative disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217019508A Division KR102738936B1 (ko) 2018-11-27 2018-11-27 골수증식 장애의 치료 방법

Publications (1)

Publication Number Publication Date
KR20250004357A true KR20250004357A (ko) 2025-01-07

Family

ID=64734125

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247040010A Pending KR20250004357A (ko) 2018-11-27 2018-11-27 골수증식 장애의 치료 방법
KR1020217019508A Active KR102738936B1 (ko) 2018-11-27 2018-11-27 골수증식 장애의 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217019508A Active KR102738936B1 (ko) 2018-11-27 2018-11-27 골수증식 장애의 치료 방법

Country Status (8)

Country Link
JP (2) JP7453230B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250004357A (cg-RX-API-DMAC7.html)
AU (1) AU2018451360B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021010134A2 (cg-RX-API-DMAC7.html)
CA (1) CA3120973A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191489A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105279SA (cg-RX-API-DMAC7.html)
WO (1) WO2020112086A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025155120A1 (ko) 2024-01-18 2025-07-24 주식회사 엘지에너지솔루션 전극조립체, 이차 전지 및 배터리 유닛

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020112939A1 (en) 2018-11-27 2020-06-04 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
WO2020112086A1 (en) * 2018-11-27 2020-06-04 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
AU2021320151A1 (en) * 2020-08-04 2023-02-23 Constellation Pharmaceuticals, Inc. 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide for treating thrombocythemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
CN106687463B (zh) 2014-06-20 2019-04-09 星座制药公司 一种乙酰胺类化合物的晶型
WO2020112086A1 (en) * 2018-11-27 2020-06-04 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025155120A1 (ko) 2024-01-18 2025-07-24 주식회사 엘지에너지솔루션 전극조립체, 이차 전지 및 배터리 유닛

Also Published As

Publication number Publication date
WO2020112086A1 (en) 2020-06-04
JP7453230B2 (ja) 2024-03-19
CA3120973A1 (en) 2020-06-04
KR102738936B1 (ko) 2024-12-06
SG11202105279SA (en) 2021-06-29
EA202191489A1 (ru) 2021-09-10
AU2018451360B2 (en) 2022-05-26
KR20210095904A (ko) 2021-08-03
JP2024063214A (ja) 2024-05-10
JP2022519425A (ja) 2022-03-24
BR112021010134A2 (pt) 2021-08-24
AU2018451360A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
KR102738936B1 (ko) 골수증식 장애의 치료 방법
US12070464B2 (en) Methods of treating myeloproliferative disorders
US20220168333A1 (en) Combination Treatment for Hematological Cancers
CN118453614A (zh) 一种改善或治疗滤泡性淋巴瘤的联合用药物组合物及其应用
US20150110774A1 (en) S100 protein inhibitors for treating leukemia
WO2021091535A1 (en) Treating myeloproliferative disorders with cpi-0610 and a jak inhibitor
US20240269146A1 (en) Use of pelabresib for treating anemias
EA047870B1 (ru) Способы лечения миелопролиферативных расстройств
KR20230110751A (ko) 골수섬유증의 치료에 사용하기 위한 cxcr1/cxcr2 억제제
WO2021091532A1 (en) Methods of treating myeloproliferative disorders
WO2020256739A1 (en) Methods of treating myeloproliferative disorders
WO2025002346A1 (zh) 含pd-l1小分子抑制剂的药物组合及其应用
US20240309079A1 (en) Combination treatment of chronic myelomonocytic leukemia in patients with ras pathway mutations
WO2024240025A1 (zh) 一种联合用药物组合物及其应用
HK40002948A (en) Combinations of imetelstat and venetoclax for the treatment of acute myeloid leukaemia
HK40002948B (en) Combinations of imetelstat and venetoclax for the treatment of acute myeloid leukaemia
CN116367839A (zh) 2-((4s)-6-(4-氯苯基)-1-甲基-4h-苯并[c]异恶唑并[4,5-e]氮杂卓-4-基)乙酰胺用于治疗血小板增多症

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20241202

Application number text: 1020217019508

Filing date: 20210623

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241231

Comment text: Request for Examination of Application

PG1501 Laying open of application